Safety and lipoprotein(a)-lowering effects of Kylo-11, a non-canonical, long-duration small interfering RNA targeting lipoprotein(a): a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial
答案Answerball
1个月前
84
10
已完结
1. 系统已在2026-09-25 14:01:33对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/s0140-6736(26)01484-4
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S0140673626014844
其他信息:
出版社: Elsevier BV
作者: Ashish Sarraju; Xiaolin Du; Luping Zhou; Luke J Laffin; Kathy Wolski; Yumei Gu; Ziyang Liu; Qinsheng Zhang; Kunyuan Cui; Xiaolan Yong; Steven E Nissen

